Navigation Links
Development of Novel Assays Vital for the European Immunoassay Diagnostics Market
Date:12/15/2008

LONDON, Dec. 15 /PRNewswire/ -- The immunoassay diagnostics market is in the late growth stage of the market lifecycle. It is being challenged by a number of factors including the commoditisation of tests, growing laboratory networks and the heightened popularity of molecular tests in areas like infectious testing. However, unmet needs in the market are propelling companies to develop novel assays and differentiate themselves to stay ahead of the competition.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.drugdiscovery.frost.com)Strategic Analysis of the European Immunoassay Market, finds that the market earned revenues of $2.97 billion in 2008 and estimates this to reach $4.20 billion in 2015.

"The future of the European immunoassay diagnostics market depends on developing novel assays in areas such as cardiology, oncology and autoimmunity," notes Frost & Sullivan Industry Analyst Arun A.K. "Rapid and efficient tests to identify disease conditions are gaining enormous importance and will set the pace in the market."

The adoption of novel assays for critical testing areas is on the rise, compelling companies to identify new biomarkers and develop assays that are easy to perform. Companies are responding well to this challenge as more than 70 immunoassays are currently in various developmental stages.

However, the centralisation of non-STAT immunoassays, together with the formation of laboratory networks in Europe, is squeezing revenue returns in the market. This situation is intensifying competition in the already crowded marketplace.

"The market will experience increasing competition through 2015," cautions Arun. "It is important, therefore, to identify key growth areas and focus on achieving differentiation in order to stay ahead of the competition."

There has been a growing trend towards collaborations among life sciences companies, research institutes and laboratories. Such alliances have aimed to identify winning strategies for the rapid and successful commercialisation of biomarkers. This will enable companies to make strong gains.

"As the usefulness of a successful biomarker ranges from disease identification to drug discovery, an integrated collaborative approach between the compatible companies in similar areas of research will help distribute developmental costs," states Arun. "Such synergistic alliances will have a mutually beneficial impact on the partners, while effecting revenue growth."

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the strategic analysis of European immunoassay diagnostics market, then send an e-mail to Patrick Cairns, Corporate Communications, at pcairns_pr@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

Strategic Analysis of the European Immunoassay Market is part of theDrug Discovery & Clinical Diagnostics Growth Partnership Services programme, which also includes research in the following markets: European POC Connectivity Market, Western European IVD Markets, and Eastern European IVD Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.

Strategic Analysis of the European Immunoassay Market

M2E3

    Contact:
    Patrick Cairns
    Corporate Communications - Europe & Africa
    P: +27 18 468 2315
    E: patrick.cairns@frost.com

http://www.frost.com/


'/>"/>
SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Isolation of a new gene family essential for early development
2. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
3. The Philadelphia Walk Now for Autism Expected to Draw 10,000 Walkers and Raise $1 Million to Help Find Answers About the Nations Fastest-Growing Developmental Disorder
4. Ovation further advances development pipeline with new phase III epilepsy study
5. Pioneer Surgical Technology Hires Vice President of New Business Development
6. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
7. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
8. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
9. Optim To Assist Prairie Community Health Center with Construction Scope Development
10. Nick Childs Joins Grey New York as Director of Content Development
11. New clues to breast cancer development in high-risk women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: